Abstract
The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r =.31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r =.28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p.001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p <.01) in the BCR-ABL expression was obtained between the major and the minor responders. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed. This indicates that the BCR-ABL expression and the tumor burden are largely independent variables.
Similar content being viewed by others
Abbreviations
- Bcr:
-
breakpoint cluster region
- bcr-abl:
-
chimera of bcr and abl gene
- BMT:
-
bone marrow transplantation
- CCA:
-
conventional cytogenetic analysis
- cDNA:
-
copy DNA
- CML:
-
chronic myeloid leukemia
- FISH:
-
fluorescence in situ hybridization
- IFN:
-
interferon
- IPC:
-
interphase cytogenetics
- M-bcr:
-
major bcr
- MMLV-RT:
-
Maloney Murine Leukemia Virus Reverse Transcriptase
- PCR:
-
polymerase chain reaction
- Ph:
-
Philadelphia chromosome
- Q-PCR:
-
quantitative reverse transcription polymerase chain reaction
- RT:
-
reverse transcription
References
Bedi A, Zehnbauer BA, Collector MI, et al: BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81: 2898–2902, 1993
Bentz M, Cabot G, Moos M, et al: Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukaemia by in situ hybridization. Blood 83: 1922–1928, 1994
Brizard F, Chomel JC, Veinstein A, et al: Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon therapy? Leukemia 12: 1076–1080, 1998
Cuneo A, Bigoni R, Emmanuel B, et al: Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 12: 1718–1723, 1998
Dewald GW, Schad CR, Christensen ER, et al: The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogen 71: 7–14, 1993
Faderl S, Talpaz M, Kantarjian HM, et al: Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93: 2755–2759, 1999
Furukawa Y, Iwase S: Antileukemic effect of interferon-a is mediated through down-modulation of E2F activity. Leukemia 11: 446–448, 1997
Gaiger A, Henn T, Hörth E, et al: Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86: 2371–2378, 1995
Garcia-Isidoro M, Tabernero MD, Garcia JL, et al: Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implication for minimal residual disease detection. Hum Pathol 28: 154–159, 1997
Hermans A, Gow J, Selleri L, et al: Bcr-abl oncogene activation in Philadelphia chromosome-positiv acute lymphoblastic leukemia. Leukemia 2: 628–633, 1988
Hochhaus A, Lin F, Reiter A, et al: Quantification of residual disease in chronic myelogeneous leukemia patients on Interferon-α therapy by competitive polymerase chain reaction. Blood 87: 1549–1555, 1996
Hochhaus A, Reiter A, Skladny H, et al: Molecular heterogeneity in complete cytogenetic responders after interferon—therapy of chronic myelogenous leukemia: levels of minimal residual disease predict risk of relapse. Blood 88 (suppl. 1): 664a. (abstr. No 2644), 1996
Hochhaus A, Lin F Reiter A, et al: Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-. Brit J Haematol 91: 126–131, 1995
Hochhaus A, Weisser A, La Rosée P, et al: Detection and quantification of residual disease in chronic myelogeneous leukemia. Leukemia 14: 998–1005, 2000
Issaad C, Ahmed M, Novault S, et al: Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia 14: 662–670, 2000
Jakab Z, Balogh E, Kiss C, et al: Biclonal chromosomal aberrations in a child with myelodysplastic syndrome. Cancer Genet Cytogen 108: 13–18, 1999
Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A concise update. Blood 82: 691–703, 1993
Kantarjian HM, O’Brien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87: 3069–3081, 1996
Kantarjian HM, Smith TL, O’Brian S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferontherapy. Ann Intern Med 122: 254–261, 1995
Keating A, Xing-Hua Wang XH, Laraya P: Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 83: 1744–1749
Lion T, Gaiger A, Henn T, et al: Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 9: 1353–1360, 1995
Moore S, Haylock DN, Levesque JP, et al: Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells. Blood 92: 2461–2470, 1998
Mühlmann J, Thaler J, Hilbe W, et al: Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during Interferon treatment: A new strategy for remission assessment. Gene Chromosome Canc 21: 90–100, 1998
Pajor L, Szuhai K, Méhes G, et al: Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukaemia. Cytometry 34: 87–94, 1998
Pajor L, Vass JA, Kereskai L, et al: Silent Philadelphia chromosome: A distinct developmental stage in a Philadelphia chromosome-positive chronic myeloproliferation? Cancer Genet Cytogen 118: 14–19, 2000
Reiter A, Marley SB, Hochhaus A, et al: BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. Brit J Haematol 102: 1271–1278, 1998
Shtivelman E, Gale RP, Dreazen O, et al: bcr-abl RNA in patients with chronic myelogenous leukaemia. Blood 69: 971–973, 1987
Talpaz M, Kantarjian HM, Kurznock R, et al: Interferon-alfa produces sustained cytogenetic responses in chronic myelogenous leukaemia Ph-chromosome positive patients. Ann Intern Med 114: 532–538, 1991
Tchirkov A, Giollant M, Tavernier F, et al: Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferontherapy. Brit J Haematol 101: 552–557, 1998
The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 330: 820–825, 1994
Verfaillie CM, Bhatia R, Miller W, et al: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 87: 4770–4779, 1996
Yanagi M, Shinjo K, Takeshita A, et al: Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 13: 542–552, 1999
Zhang JG, Lin F, Chase A, et al: Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 87: 2588–2593, 1996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kereskai, L., Vass, J.A., Kneif, M. et al. Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients. Pathol. Oncol. Res. 9, 174–179 (2003). https://doi.org/10.1007/BF03033733
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03033733